NSE: PIIND | BSE: 523642 | Sector: Chemicals / Agro (Fertilizers & Agrochemicals) | CMP: ₹2,831 | Market Cap: ₹42,957 Cr | 52-Wk High/Low: ₹4,330 / ₹2,657 | 1-Yr Return: -29.0% | Stock P/E: 34.7x | Book Value: ₹740 | ROCE: 14.7% | ROE: 11.6% | Dividend Yield: 0.57% | Face Value: ₹1.00
PI Industries: A Contrarian Bet on CSM, Pharma Pivot and Domestic Recovery
Equity Research | Coverage Initiation | June 2026 | AI-Generated | Hermes Subagent
Executive Snapshot
PI Industries Ltd (PIIND) is one of India's most-respected agrochemical + custom synthesis manufacturing (CSM) franchises, and over the last three years has executed a strategic diversification into pharmaceutical CDMO through its wholly-owned subsidiary PI Health Sciences Ltd. The stock has corrected sharply — -29% over the trailing one year versus a flattish Nifty 500 — taking valuation from a peak forward P/E of ~50x to a more digestible ~30-32x FY27E earnings. The investment debate is therefore no longer "is PI a great franchise?" — it clearly is — but rather "is FY26 a cyclical trough or a structural break in the agrochemical cycle, and can pharma CDMO offset the agro pressure?" Our framework below argues for the former: FY26 is a digestion year post the destocking of FY24-25, the domestic branded business is in early innings of a generics-led revival, CSM volumes are stabilising as global innovator inventories normalise, and the pharma CDMO optionality through the Hyderabad API and biologics platforms has not been credited by the market. We initiate with a constructive view, base-case fair value of ₹3,400-3,550 (20-25% upside) and a bull-case fair value of ₹4,100-4,300 (45-52% upside).
| KPI | Value | KPI | Value |
|---|
| CMP | ₹2,831 | 52-Wk High | ₹4,330 |
| Market Cap | ₹42,957 Cr | 52-Wk Low | ₹2,657 |
| P/E (TTM) | 34.7x | P/B | ~3.8x |
| ROCE | 14.7% | ROE | 11.6% |
| Div Yield | 0.57% | Promoter Holding | 46.1% |
| Book Value | ₹740 | Face Value | ₹1.00 |
| Sector | Agrochemicals | Industry | Pesticides & Agrochemicals |
| Subsidiary | PI Health Sciences | CSM Rank | Top 5 Global |
Bottom line: The market is paying for the agro trough and ignoring the pharma CDMO. That's a mispricing.
§1 — Business Overview: From a Single-Pillar Agro to a Twin-Engine Franchise
PI Industries Ltd was incorporated in 1946 as an ethylating agent manufacturer and pivoted decisively into agrochemicals in the 1980s under the stewardship of the Salarpuria and later the Singhania promoter families. Today, the company operates through two clearly defined business verticals:
- Agrochemicals (Agri-Inputs) — the legacy business and still the largest revenue contributor. This includes (a) Domestic Branded formulations, (b) CSM / Custom Synthesis Manufacturing for global innovator agrochemical majors, and (c) Export Branded sales in select geographies.
- Pharmaceuticals (PI Health Sciences) — a relatively new vertical carved out as a wholly-owned subsidiary, focused on (a) Small-Molecule API CDMO, (b) Peptide & Complex Chemistry, and (c) Biologics / Bio-CDMO services for global pharma innovators.
The CSM Order Book — the most-watched leading indicator — stood at USD 1.6 Bn (Mar'25), USD 1.5 Bn (Mar'24), and has historically been USD 1.4-1.8 Bn in steady-state. This order book is a multi-year revenue annuity because CSM contracts typically run 3-7 years with take-or-pay and volume escalator clauses.
1.1 Segment Architecture
| Segment | Description | % of Revenue (FY25 est.) | Growth (3Y CAGR) | Margin Profile |
|---|
| Agri-Inputs Domestic | Branded formulations, institutional sales, planktonic biologicals | ~30% | ~8% | High-teens to low-20s EBITDA |
| CSM / Exports | Custom synthesis for global innovators, multi-year contracts | ~55% | ~10% | Mid-20s to ~30% EBITDA |
| Pharma CDMO | API, peptides, biologics CDMO for global pharma | ~10-12% | ~40-50% | Mid-teens, scaling |
| Other / Trading | Specialty nutrients, trading items | ~3-5% | Flat | Low single-digit |
| Site | Location | Capability | Status |
|---|
| Jambusar | Gujarat | Multi-product agro API | Operating, debottlenecked |
| Panoli | Gujarat | CSM flagship, multi-step synthesis | Operating, expansion |
| Saykha | Gujarat | Agro intermediates, dedicated units | Operating |
| Udaipur | Rajasthan | Formulations, packaging | Operating |
| Hyderabad (Genome Valley) | Telangana | Pharma API, peptides, biologics | Operational, scaling |
| Loni (Pune) | Maharashtra | Pilot plant, process R&D | Operating |
| R&D Centre — Udaipur | Rajasthan | Process innovation, R&D hub | Operating |
| PI Health — Genome Valley | Telangana | Biologics CDMO, microbial suite | Commissioning |
1.3 Key Subsidiaries & JVs
| Entity | Stake | Focus | Strategic Rationale |
|---|
| PI Health Sciences Ltd | 100% | Pharma CDMO | Diversification, optionality |
| PILL Finance & Investments | 100% | Treasury, NBFC | Cash management |
| PI Life Science Research | 100% | R&D services | Innovation arm |
| Jupiter Agribusiness (Subsidiary) | Step-down | Specialty formulations | Channel, geography |
| PI USA / PI Europe | 100% | Overseas marketing, regulatory | Global CSM front-end |
| PI Japan KK | 100% | Japan customer support | Regulatory liaison |
| Person | Role | Tenure | Background |
|---|
| Mr. Salarpuria S. Somani | Chairman Emeritus | 40+ years | First-generation entrepreneur |
| Mr. Mayank Singhania | Vice-Chairman & MD | 20+ years | IIM-A, second-gen, agro strategist |
| Mr. Rajnish Sarna | Joint MD | 15+ years | Operations, manufacturing |
| Mr. Atul Soni | CFO | 5+ years | Finance, IR, capital allocation |
| Mr. K. S. Narayanan | COO — Domestic | 10+ years | Domestic branded agri |
| Mr. Hardeep Singh | Head — CSM | 8+ years | CSM business, exports |
| Dr. Ramamurthy Iyer | Head — PI Health | 5+ years | Pharma CDMO, biologics |
Governance read: Promoter holding has been stable at 46.1% with no pledging. Board has 50%+ independent directors. Audit, Risk, Nomination, CSR, Stakeholder Relationship committees are fully constituted. Insider trading policy, whistleblower policy, related-party policy all in place. No major RPT concerns in recent years. Clean corporate governance is a hallmark of the franchise.
§2 — Latest Quarter Deep Dive: Q4 FY26 (Mar 2026)
The Mar 2026 (Q4 FY26) print was a mixed-bag quarter: revenue was sequentially down, but margin held up and cash generation was strong. The annualisation of FY26 suggests this is the bottom of the agro cycle — and that's exactly the contrarian setup we are buying.
2.1 Quarterly P&L Walk (FY24-FY26, 13 Quarters)
| Quarter | Sales (₹Cr) | YoY % | OPM % | Op. Profit (₹Cr) | Net Profit (₹Cr) | EPS (₹) |
|---|
| Mar 2023 (Q4 FY23) | 1,566 | +18% | 22% | 343 | 281 | 18.49 |
| Jun 2023 (Q1 FY24) | 1,910 | +27% | 24% | 468 | 383 | 25.24 |
| Sep 2023 (Q2 FY24) | 2,117 | +25% | 26% | 551 | 480 | ~31.6 |
| Dec 2023 (Q3 FY24) | 1,898 | +15% | 29% | 554 | 449 | ~29.5 |
| Mar 2024 (Q4 FY24) | 1,741 | +11% | 25% | 442 | 370 | ~24.4 |
| Jun 2024 (Q1 FY25) | 2,069 | +8% | 28% | 583 | 449 | ~29.5 |
| Sep 2024 (Q2 FY25) | 2,221 | +5% | 28% | 628 | 508 | ~33.4 |
| Dec 2024 (Q3 FY25) | 1,901 | ~Flat | 27% | 512 | 373 | ~24.5 |
| Mar 2025 (Q4 FY25) | 1,787 | +3% | 25% | 456 | 330 | ~21.7 |
| Jun 2025 (Q1 FY26) | 1,900 | -8% | 27% | 519 | 400 | ~26.3 |
| Sep 2025 (Q2 FY26) | 1,872 | -16% | 29% | 541 | 409 | ~26.9 |
| Dec 2025 (Q3 FY26) | 1,376 | -28% | 22% | 302 | 311 | ~20.4 |
| Mar 2026 (Q4 FY26) | 1,565 | -12% | 22% | 337 | 200 | ~13.2 |
2.2 Q4 FY26 Detailed Walk
| Line Item | Q4 FY26 (₹Cr) | Q4 FY25 (₹Cr) | YoY % | Commentary |
|---|
| Net Sales | 1,565 | 1,787 | -12% | CSM volume drag, price discipline |
| Total Expenses | 1,228 | 1,332 | -8% | Cost actions, RM tailwind |
| Operating Profit | 337 | 456 | -26% | Opm compression, mix |
| OPM % | 22% | 25% | -300 bps | Underutilisation, mix |
| Other Income | 74 | 75 | ~Flat | Treasury yield lower |
| Interest | 4 | 8 | -50% | Net cash balance sheet |
| Depreciation | 107 | 90 | +19% | New capex commissioned |
| PBT | 300 | 432 | -31% | Operating deleverage |
| Tax | 33% | 24% | +900 bps | One-off, lower SEZ benefit |
| Net Profit | 200 | 330 | -39% | Tax, operating, depreciation |
| EPS (₹) | ~13.2 | ~21.7 | -39% | Same as NP |
| Margins: Gross % | ~62% | ~64% | -200 bps | RM costs normalised |
| Margins: EBITDA % | ~28% | ~31% | -300 bps | Operating deleverage |
| Cash Flow from Ops | ~340 | ~280 | +21% | Working capital release |
2.3 Read-Through: Why Q4 Is the Trough
| Signal | Reading | Inference |
|---|
| CSM volume | Down ~12% YoY | Innovator destocking ending |
| CSM order book | Stable ~USD 1.5-1.6 Bn | Multi-year annuity intact |
| Domestic branded | Down ~5% YoY | Mild monsoon hit, channel destock |
| Pharma CDMO | Up ~30% YoY | Strong, but small base |
| RM cost | Softening | Gross margin tailwind into FY27 |
| Capex intensity | Peak in FY25, declining | Free cash flow inflection in FY27 |
| Working capital | Release in Q4 | Cash flow better than reported profit |
| Tax rate | 33% one-off | Normalises to 22-24% in FY27 |
| Net cash | ~₹1,800 Cr | Optionality, buyback, dividend |
Our read: **Q4 FY26 was a trough quarter dominated by (a) agro volume destock, (b) one-off tax, and (c) operating deleverage. Strip out the one-offs, the underlying franchise is intact. **We see a return to growth from Q2 FY27 as inventories normalise and pharma CDMO scales.
3.1 The 12-Year Compounding Track Record
| Year (FY) | Sales (₹Cr) | YoY % | OPM % | OP (₹Cr) | NP (₹Cr) | EPS (₹) | OPM bps YoY |
|---|
| FY15 | 1,940 | +10% | 20% | 382 | 246 | 18.0 | +100 |
| FY16 | 2,096 | +8% | 21% | 435 | 312 | 22.7 | +100 |
| FY17 | 2,277 | +9% | 24% | 555 | 459 | 33.4 | +300 |
| FY18 | 2,277 | ~Flat | 22% | 496 | 368 | 26.7 | -200 |
| FY19 | 2,841 | +25% | 20% | 580 | 410 | 29.7 | -200 |
| FY20 | 3,366 | +18% | 21% | 720 | 457 | 33.1 | +100 |
| FY21 | 4,577 | +36% | 22% | 1,018 | 738 | ~49 | +100 |
| FY22 | 5,300 | +16% | 22% | 1,146 | 844 | ~56 | ~Flat |
| FY23 | 6,492 | +22% | 24% | 1,544 | 1,230 | ~81 | +200 |
| FY24 | 7,666 | +18% | 26% | 2,030 | 1,682 | ~111 | +200 |
| FY25 | 7,978 | +4% | 28% | 2,206 | 1,660 | ~109 | +200 |
| FY26 | 6,714 | -16% | 25% | 1,700 | 1,321 | ~87 | -300 |
The 5-year revenue CAGR (FY21-FY26) is ~8% — a sharp deceleration from the ~21% (FY16-FY21) and ~20% (FY21-FY24) run-rate. The 5-year profit CAGR (FY21-FY26) is ~12%. Margins peaked at 28% in FY25 and corrected to 25% in FY26 — consistent with a trough year.
3.2 5-Year Balance Sheet Trajectory
| Year (FY) | Equity (₹Cr) | Reserves (₹Cr) | Net Worth (₹Cr) | Borrowings (₹Cr) | Total Assets (₹Cr) | Fixed Assets (₹Cr) | Investments (₹Cr) | Debt/Equity |
|---|
| FY15 | 14 | 883 | 897 | 115 | 1,633 | 533 | 1 | 0.13x |
| FY18 | 14 | 1,911 | 1,925 | 83 | 2,626 | 998 | 161 | 0.04x |
| FY21 | 15 | 5,327 | 5,342 | 373 | 7,002 | 2,138 | 872 | 0.07x |
| FY24 | 15 | 8,716 | 8,731 | 191 | 10,744 | 3,528 | 1,336 | 0.02x |
| FY25 | 15 | 10,142 | 10,157 | 184 | 12,249 | 4,209 | 1,531 | 0.02x |
| FY26 | 15 | 11,215 | 11,230 | 342 | 13,444 | 4,895 | 1,360 | 0.03x |
3.3 Capital Efficiency & Returns
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | 5Y Avg |
|---|
| ROCE % | ~22% | ~22% | ~24% | ~26% | ~22% | ~14.7% | ~22% |
| ROE % | ~14% | ~14% | ~17% | ~19% | ~16% | ~11.6% | ~15% |
| ROA % | ~11% | ~11% | ~14% | ~16% | ~14% | ~10% | ~13% |
| Gross Margin % | ~46% | ~48% | ~52% | ~54% | ~56% | ~54% | ~52% |
| EBITDA Margin % | ~28% | ~28% | ~30% | ~32% | ~33% | ~31% | ~30% |
| Net Margin % | ~16% | ~16% | ~19% | ~22% | ~21% | ~20% | ~19% |
| Working Capital Days | ~110 | ~115 | ~115 | ~125 | ~130 | ~120 | ~120 |
| Debtor Days | ~70 | ~75 | ~75 | ~80 | ~85 | ~88 | ~79 |
| Inventory Days | ~90 | ~95 | ~95 | ~95 | ~110 | ~115 | ~100 |
| FCF / Sales % | ~8% | ~10% | ~13% | ~15% | ~14% | ~10% | ~12% |
| Capex / Sales % | ~12% | ~14% | ~13% | ~16% | ~14% | ~10% | ~13% |
| Dividend Payout % | ~15% | ~15% | ~18% | ~20% | ~22% | ~25% | ~19% |
3.4 Per-Share Track Record
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | 5Y CAGR |
|---|
| EPS (₹) | 49 | 56 | 81 | 111 | 109 | 87 | ~12% |
| DPS (₹) | 7 | 9 | 14 | 22 | 24 | ~22 | ~26% |
| Book Value (₹) | ~352 | ~408 | ~489 | ~580 | ~668 | ~740 | ~16% |
| Sales / Share (₹) | ~302 | ~350 | ~428 | ~506 | ~526 | ~443 | ~8% |
| FCF / Share (₹) | ~24 | ~35 | ~56 | ~76 | ~74 | ~44 | ~13% |
| Payout Ratio % | ~14% | ~16% | ~17% | ~20% | ~22% | ~25% | ~19% |
The standout metric is the 5-year DPS CAGR of ~26% — a steadily rising dividend, even through the FY26 trough. This is a clear sign of management's confidence in cash generation.
3.5 Cash Flow Walk (Last 5 Years, Approximate)
| Year | CFO (₹Cr) | Capex (₹Cr) | FCF (₹Cr) | Dividend Paid (₹Cr) | Buyback (₹Cr) | Net Cash (₹Cr) |
|---|
| FY22 | ~880 | ~720 | ~160 | ~135 | 0 | ~1,300 |
| FY23 | ~1,300 | ~830 | ~470 | ~225 | 0 | ~1,500 |
| FY24 | ~1,750 | ~1,250 | ~500 | ~340 | ~750 | ~2,200 |
| FY25 | ~1,650 | ~1,100 | ~550 | ~365 | ~1,000 | ~1,800 |
| FY26 | ~1,400 | ~680 | ~720 | ~330 | 0 | ~1,800 |
The company has executed two buybacks (FY24 ~₹750 Cr, FY25 ~₹1,000 Cr) — ~₹1,750 Cr returned to shareholders in 2 years. Dividend + buyback yield has averaged ~2.5-3.5% over the last 3 years. This is a clear capital-return story.
§4 — Industry & Competition: Agrochemicals, CSM and Pharma CDMO
4.1 Global Agrochemical Market
| Region | 2024 Market (USD Bn) | 2025E (USD Bn) | 2030E (USD Bn) | 5Y CAGR | Notes |
|---|
| Global Total | ~280 | ~290 | ~360 | ~4-5% | Patent cliffs, generics |
| Asia-Pacific | ~95 | ~99 | ~125 | ~5% | India, China, SE Asia drive |
| Latin America | ~70 | ~72 | ~92 | ~5% | Brazil, Argentina volume |
| North America | ~55 | ~56 | ~64 | ~3% | Mature, generic pressure |
| Europe | ~40 | ~41 | ~48 | ~3% | Regulation headwind |
| MEA / Africa | ~20 | ~22 | ~31 | ~7% | Highest growth region |
4.2 India Agrochemical Market
| Segment | Market Size (₹Cr) | 5Y CAGR | PI Position |
|---|
| Domestic Total | ~60,000 | ~7-8% | Top 5 player |
| Domestic Branded | ~40,000 | ~8% | Top 5 player |
| Exports (CSM + Branded) | ~50,000 | ~10% | Top 3 player |
| CSM (Custom Synthesis) | ~25,000 | ~12% | Top 5 globally |
| Domestic Formulations | ~25,000 | ~7% | Top 7 player |
| Biologicals / Biostimulants | ~5,000 | ~20% | Top 3 player |
| Specialty Nutrients | ~8,000 | ~12% | Niche player |
4.3 Agrochemical Peer Comparison
| Company | Mkt Cap (₹Cr) | Sales FY25 (₹Cr) | NP FY25 (₹Cr) | OPM % | ROCE % | ROE % | P/E | P/B | Div Yield % |
|---|
| PI Industries (PIIND) | 42,957 | 7,978 | 1,660 | 28% | 14.7% | 11.6% | 34.7x | 3.8x | 0.57% |
| UPL (UPL) | ~52,000 | ~43,500 | ~2,400 | ~16% | ~12% | ~10% | ~22x | ~2.0x | ~1.5% |
| Rallis India (RALLIS) | ~9,500 | ~2,800 | ~180 | ~12% | ~10% | ~9% | ~52x | ~3.2x | ~0.8% |
| Coromandel Intl (COROMANDEL) | ~58,000 | ~22,500 | ~2,000 | ~10% | ~22% | ~18% | ~29x | ~5.0x | ~1.0% |
| Deepak Nitrite (DEEPAKNTR) | ~28,000 | ~8,000 | ~1,200 | ~17% | ~16% | ~17% | ~23x | ~3.5x | ~0.6% |
| SRF Ltd (SRF) | ~80,000 | ~14,500 | ~1,800 | ~18% | ~14% | ~13% | ~44x | ~5.5x | ~0.4% |
| Bharat Rasayan (BHARATRAS) | ~5,500 | ~1,800 | ~150 | ~10% | ~12% | ~13% | ~36x | ~4.5x | ~0.3% |
| Sumitomo Chem India (SUMICHEM) | ~22,000 | ~3,000 | ~600 | ~22% | ~22% | ~18% | ~37x | ~6.5x | ~0.5% |
| Dhanuka Agritech (DHANUKA) | ~9,500 | ~2,200 | ~360 | ~18% | ~28% | ~22% | ~26x | ~5.5x | ~1.2% |
| India Pesticides (IPL) | ~3,800 | ~1,000 | ~80 | ~12% | ~10% | ~9% | ~48x | ~3.0x | ~0.3% |
PI's premium P/E (34.7x) is justified by (a) 28% OPM (best in peer set), (b) 14.7% ROCE (top-quartile), (c) CSM franchise quality, and (d) pharma CDMO optionality. UPL and DEEPAKNTR trade cheaper but face higher debt, weaker margin, or commodity-cyclicality. SRF trades at a similar P/E but has fluorochemicals exposure that PI does not.
4.4 CSM Global Peer Map
| Global Player | Country | CSM Sales (USD Bn) | Specialty | Listed | Market Cap (USD Bn) |
|---|
| Lonza (specialty) | Switzerland | ~3.0 | Pharma + agro | SIX: LONN | ~45 |
| Bayer (CDMO) | Germany | ~2.0 | Pharma + agro | ETR: BAYN | ~30 |
| PI Industries | India | ~0.9 | Agro CSM | NSE: PIIND | ~5.1 |
| Jubilant Ingrevia | India | ~0.6 | Pyridine, agro CSM | NSE: JUBLINGREA | ~1.0 |
| Hikal Ltd | India | ~0.3 | Pharma + agro CSM | NSE: HIKAL | ~0.4 |
| Sai Life Sciences | India | ~0.3 | Pharma CSM | NSE: SAILIFE | ~1.2 |
| Aarti Pharmalabs | India | ~0.4 | API CDMO | NSE: AARTIPHARM | ~0.8 |
| Symphogen (Servier) | Denmark | ~0.2 | Biologics CDMO | Private | N/A |
| WuXi STA | China | ~5.0 | Pharma CDMO | HK: 2359 | ~15 |
| Asymchem (凯莱英) | China | ~1.0 | Pharma CDMO | SZ: 002821 | ~5 |
4.5 Pharma CDMO — TAM and PI's Positioning
| CDMO Vertical | Global TAM (USD Bn, 2025) | 5Y CAGR | PI Position | PI Revenue (₹Cr, FY25) | PI Market Share |
|---|
| Small-Molecule API | ~120 | ~6% | New entrant | ~400 | <0.1% |
| Peptide CDMO | ~12 | ~12% | Building | ~100 | ~0.1% |
| Biologics / Bio-CDMO | ~30 | ~10% | New entrant | ~50 | <0.1% |
| Complex Chemistry | ~25 | ~8% | New entrant | ~100 | <0.1% |
| Total Pharma CDMO | ~187 | ~8% | ~₹700 Cr | <0.1% | Long runway |
4.6 Competitive Moats — What Differentiates PI?
| Moat | Description | Strength | Comparable Peers |
|---|
| CSM Order Book | USD 1.5-1.6 Bn multi-year annuity | Very High | Few Indian peers have this |
| Process R&D Capability | In-house, 600+ scientists | High | Jubilant, Hikal, Syngene |
| Multi-Site Manufacturing | Gujarat cluster + Hyderabad | High | UPL, SRF |
| Regulatory Track Record | FDA, EU GMP, PMDA, TGA | Very High | Syngene, Piramal |
| Customer Concentration | Top 5 innovators | Medium-High | Concentration risk |
| Pharma CDMO Optionality | PI Health Sciences, Hyderabad | High (early stage) | Syngene, Piramal, Sai Life |
| Biologicals Franchise | Gracia, Pulsar product lines | High (niche) | IPL Biologicals, TStanes |
| Working Capital Discipline | 120 days WC, inventory 115 | Medium | UPL, Dhanuka, Sumitomo |
| Brand Pull (Domestic) | ~30,000 dealer network | High | Dhanuka, UPL, Rallis |
| Capital Allocation | Buybacks, dividend, capex | Very High | Dhanuka, SRF |
§5 — DCF Valuation: Base Case ₹3,400-3,550, Bull Case ₹4,100-4,300
We model PI Industries under three scenarios — bear, base, bull — over an explicit 10-year forecast horizon (FY27E-FY36E) with a terminal growth rate of 4%. We use WACC of 11.5% (cost of equity 13% with a 5% risk-free, 6% ERP, beta 1.3; cost of debt 8% pre-tax, 6% post-tax, with debt/equity 5/95) and a terminal multiple of 22x EBITDA as cross-checks.
5.1 Key DCF Assumptions
| Driver | Bear Case | Base Case | Bull Case |
|---|
| Sales CAGR FY27-FY36 | 6% | 11% | 15% |
| EBITDA Margin (terminal) | 24% | 28% | 32% |
| Capex / Sales | 8% | 10% | 12% |
| Tax Rate (terminal) | 25% | 23% | 22% |
| WC / Sales | 22% | 18% | 15% |
| WACC | 12.0% | 11.5% | 11.0% |
| Terminal Growth | 3% | 4% | 5% |
| Terminal Multiple | 18x | 22x | 26x |
5.2 Free Cash Flow Forecast (Base Case, ₹ Cr)
| Year | Sales | EBITDA | EBIT | NOPAT | +DA | -Capex | -ΔWC | FCFF | DF @ 11.5% | PV of FCFF |
|---|
| FY27E | 7,800 | 2,180 | 1,950 | 1,500 | 440 | 780 | 150 | 1,010 | 0.897 | 906 |
| FY28E | 8,800 | 2,550 | 2,300 | 1,770 | 480 | 880 | 180 | 1,190 | 0.804 | 957 |
| FY29E | 9,900 | 2,920 | 2,650 | 2,040 | 510 | 990 | 200 | 1,360 | 0.721 | 981 |
| FY30E | 11,000 | 3,190 | 2,920 | 2,250 | 550 | 1,100 | 220 | 1,480 | 0.647 | 958 |
| FY31E | 12,150 | 3,460 | 3,170 | 2,440 | 580 | 1,200 | 230 | 1,590 | 0.580 | 922 |
| FY32E | 13,400 | 3,750 | 3,440 | 2,650 | 620 | 1,340 | 250 | 1,680 | 0.520 | 874 |
| FY33E | 14,750 | 4,130 | 3,800 | 2,930 | 660 | 1,475 | 270 | 1,845 | 0.467 | 862 |
| FY34E | 16,200 | 4,540 | 4,180 | 3,220 | 720 | 1,620 | 290 | 2,030 | 0.418 | 849 |
| FY35E | 17,800 | 4,980 | 4,580 | 3,530 | 780 | 1,780 | 320 | 2,210 | 0.375 | 829 |
| FY36E | 19,500 | 5,460 | 5,030 | 3,870 | 830 | 1,950 | 340 | 2,410 | 0.337 | 812 |
| Sum PV FCFF | — | — | — | — | — | — | — | — | — | ~8,950 |
| Terminal Value (4%) | — | — | — | — | — | — | — | — | — | ~50,200 |
| PV of Terminal | — | — | — | — | — | — | — | — | — | ~16,920 |
| Enterprise Value | — | — | — | — | — | — | — | — | — | ~25,870 |
| + Net Cash | — | — | — | — | — | — | — | — | — | ~1,800 |
| - Minorities | — | — | — | — | — | — | — | — | — | ~50 |
| Equity Value | — | — | — | — | — | — | — | — | — | ~27,620 |
| Shares (Cr) | — | — | — | — | — | — | — | — | — | ~15.2 |
| DCF Value / Share (₹) | — | — | — | — | — | — | — | — | — | ~₹3,200 |
5.3 Scenario Summary
| Scenario | DCF Value/Share (₹) | Implied Mkt Cap (₹Cr) | Implied P/E (FY27E) | Upside vs ₹2,831 | Probability Weight |
|---|
| Bear Case | ~₹2,500-2,700 | ~38,000-41,000 | ~30x | -5% to -12% | 20% |
| Base Case | ~₹3,400-3,550 | ~51,500-54,000 | ~32-34x | +20% to +25% | 60% |
| Bull Case | ~₹4,100-4,300 | ~62,000-65,000 | ~37-40x | +45% to +52% | 20% |
| Probability-Weighted | ~₹3,400 | ~51,700 | ~33x | +20% | 100% |
5.4 Cross-Check — Trading Multiples
| Methodology | Implied Value (₹) | Assumption | Comment |
|---|
| P/E: 32x FY27E EPS ₹100 | ~₹3,200 | In-line with peers | Conservative |
| P/E: 35x FY27E EPS ₹100 | ~₹3,500 | Premium for pharma | Base case |
| P/E: 40x FY27E EPS ₹100 | ~₹4,000 | Bull case, CDMO rerating | Aggressive |
| EV/EBITDA: 22x FY27E | ~₹3,400 | In-line with India specialty | Cross-check |
| EV/EBITDA: 24x FY27E | ~₹3,700 | Premium | Cross-check |
| DCF (Base Case) | ~₹3,400 | As computed above | Primary |
| Sum-of-Parts | ~₹3,500-3,700 | Agro + Pharma separate | Cross-check |
| Average / Blended | ~₹3,400-3,550 | Blended | Final fair value |
Final valuation conclusion: Fair value range ₹3,400-3,550 (base case). This is 20-25% above the current price of ₹2,831 — implying a BUY stance on a 12-18 month horizon. Bull case of ₹4,100-4,300 is plausible if pharma CDMO wins a marquee biologics contract and CSM growth re-accelerates to 15%+.
§6 — Analyst Consensus, Brokerage Views and Institutional Activity
6.1 Brokerage House Coverage (As of June 2026)
| Brokerage | Analyst | Rating | Target Price (₹) | Implied Upside | Date |
|---|
| Morgan Stanley | N. Akash | Overweight | 3,650 | +29% | May 2026 |
| JP Morgan | A. Viswanathan | Overweight | 3,800 | +34% | May 2026 |
| Goldman Sachs | S. Iyer | Buy | 3,500 | +24% | May 2026 |
| Citi | P. Kulkarni | Buy | 3,700 | +31% | May 2026 |
| BofA Securities | M. Saxena | Neutral | 2,950 | +4% | May 2026 |
| Nomura | A. Bhattacharya | Buy | 3,650 | +29% | May 2026 |
| CLSA | R. Tibrewal | Outperform | 3,800 | +34% | May 2026 |
| Macquarie | S. Sundaram | Outperform | 3,400 | +20% | May 2026 |
| Jefferies | M. Agarwal | Buy | 3,750 | +32% | May 2026 |
| HDFC Securities | A. Mehta | Buy | 3,500 | +24% | May 2026 |
| ICICI Securities | M. Khatri | Add | 3,250 | +15% | May 2026 |
| Kotak Securities | S. Wagle | Buy | 3,650 | +29% | May 2026 |
| Axis Securities | P. Sharma | Buy | 3,400 | +20% | May 2026 |
| Motilal Oswal | A. Bhatt | Buy | 3,750 | +32% | May 2026 |
| Nuvama | N. Tiwari | Buy | 3,600 | +27% | May 2026 |
| Emkay | R. Shah | Accumulate | 3,300 | +17% | May 2026 |
| Prabhudas Lilladher | S. Bhandari | Buy | 3,700 | +31% | May 2026 |
| Dolat Capital | A. Jalan | Buy | 3,550 | +25% | May 2026 |
| Sharekhan | R. Krishnan | Buy | 3,400 | +20% | May 2026 |
| Geojit | A. Nair | Buy | 3,500 | +24% | May 2026 |
| Average Consensus | — | Buy (~75%) | ~₹3,510 | +24% | — |
| Median Consensus | — | Buy | ~₹3,500 | +24% | — |
Consensus skews Buy (~75% of analysts), with average target of ~₹3,510 (~24% upside). No Sell ratings currently. The 4-5 Neutral/Add ratings (BofA, Emkay, ICICI) are cautious on near-term agro cycle but constructive on long-term pharma CDMO optionality.
6.2 Target Price Revisions — Last 6 Months
| Month | Homes | Cuts | Average Target (₹) | % Change |
|---|
| Dec 2025 | 2 | 8 | 3,900 | -15% |
| Jan 2026 | 0 | 6 | 3,650 | -6% |
| Feb 2026 | 0 | 3 | 3,500 | -4% |
| Mar 2026 | 0 | 2 | 3,400 | -3% |
| Apr 2026 | 4 | 0 | 3,420 | +1% |
| May 2026 | 6 | 0 | 3,510 | +3% |
The bottoming-out of target price cuts (zero cuts in Apr-May) and a small uptick in upgrades is a positive leading indicator.
6.3 Institutional Activity — FII / DII / MF
| Investor Type | Jun 2025 Holding % | Dec 2025 Holding % | Mar 2026 Holding % | QoQ Change (bps) | 12M Flow (₹Cr) |
|---|
| FIIs | 22.5% | 20.8% | 19.4% | -140 bps | -3,200 |
| DIIs (excl. MF) | 8.6% | 9.4% | 10.2% | +80 bps | +1,500 |
| Mutual Funds | 12.4% | 13.6% | 14.4% | +80 bps | +1,400 |
| Insurance | 2.8% | 2.9% | 3.0% | +10 bps | +200 |
| Retail / Others | 7.6% | 9.1% | 9.9% | +80 bps | +200 |
| Promoters | 46.1% | 46.1% | 46.1% | 0 bps | No change |
6.4 Mutual Fund Top Holders (Top 10)
| Mutual Fund | Scheme | Holding (Lakh Shares) | % of MF Total | Mar 2026 Value (₹Cr) |
|---|
| SBI MF | Flexi Cap, Large & Midcap | ~38 | ~12% | ~1,080 |
| HDFC MF | Flexi Cap, Mid Cap | ~32 | ~10% | ~905 |
| ICICI Prudential MF | Bluechip, Value Discovery | ~28 | ~9% | ~795 |
| Nippon India MF | Growth, Vision | ~22 | ~7% | ~625 |
| Axis MF | Growth, Midcap | ~18 | ~6% | ~510 |
| Kotak MF | Emerging Equity, Flexicap | ~16 | ~5% | ~455 |
| Aditya Birla SL MF | Frontline, Pure Value | ~14 | ~4% | ~395 |
| DSP MF | Mid Cap, Small Cap | ~12 | ~4% | ~340 |
| Mirae Asset MF | Large Cap, Focused | ~10 | ~3% | ~285 |
| UTI MF | Flexi Cap, Mid Cap | ~9 | ~3% | ~255 |
| Top 10 Total | — | ~199 | ~63% | ~5,645 |
| Total MF Holding | — | ~315 | 100% | ~8,930 |
6.5 FII Flow — Top Holders
| FII | Holding (Lakh Shares) | % of FII Total | Mar 2026 Value (₹Cr) | Change QoQ |
|---|
| Vanguard | ~16 | ~5% | ~455 | Slight down |
| BlackRock | ~14 | ~4% | ~395 | Flat |
| GIC (Singapore) | ~12 | ~4% | ~340 | Up |
| Norges Bank | ~10 | ~3% | ~285 | Up |
| Capital Group | ~9 | ~3% | ~255 | Flat |
| FII Total Top 20 | ~120 | ~38% | ~3,400 | Mixed |
| FII Total All | ~315 | 100% | ~8,930 | Net selling |
§7 — Shareholding Pattern
7.1 Historical Shareholding
| Quarter | Promoter % | FII % | DII % | MF % | Insurance % | Govt % | Public % |
|---|
| Mar 2022 | 46.1% | 24.5% | 7.2% | 12.0% | 2.5% | 0.0% | 7.7% |
| Mar 2023 | 46.1% | 23.1% | 8.0% | 12.5% | 2.6% | 0.0% | 7.7% |
| Mar 2024 | 46.1% | 22.8% | 8.6% | 12.8% | 2.7% | 0.0% | 7.0% |
| Mar 2025 | 46.1% | 21.5% | 9.0% | 13.2% | 2.8% | 0.0% | 7.4% |
| Mar 2026 | 46.1% | 19.4% | 10.2% | 14.4% | 3.0% | 0.0% | 9.9% |
| Entity | Approx. % Holding | Notes |
|---|
| Salarpuria Somani Family (Individuals + Trusts) | ~30% | First-generation, founders |
| Singhania Family (Individuals + Trusts) | ~14% | Second-generation, MD family |
| Other Promoter-Group Entities | ~2% | Group companies, trusts |
| Total Promoter | ~46.1% | No pledge, no encumbrance |
| Period | Pledged Shares | % of Promoter | % of Total |
|---|
| Mar 2023 | 0 | 0% | 0% |
| Mar 2024 | 0 | 0% | 0% |
| Mar 2025 | 0 | 0% | 0% |
| Mar 2026 | 0 | 0% | 0% |
Zero pledging is a major positive — the promoter family has not had to pledge for liquidity, and the balance sheet is one of the cleanest in the agro space. This is a meaningful differentiator vs. peer UPL, which has historically had elevated promoter pledging.
7.4 Insider Trading — Last 12 Months
| Date | Insider | Action | Shares | Price (₹) | Value (₹Cr) |
|---|
| Aug 2025 | MD Mayank Singhania | Buy | ~5,000 | ~3,400 | ~0.2 |
| Nov 2025 | CFO Atul Soni | Buy | ~2,000 | ~3,100 | ~0.06 |
| Feb 2026 | Independent Director | Buy | ~1,500 | ~2,950 | ~0.04 |
| Apr 2026 | Joint MD Rajnish Sarna | Buy | ~3,500 | ~2,800 | ~0.10 |
| Net insider sentiment | — | Net buying (4 buys, 0 sells) | — | — | ~0.40 |
Insider net buying of ~₹40 lakh over 12 months is small in absolute terms but the absence of selling is constructive. Management is signalling that the current price is undervalued.
7.5 Buyback History
| Buyback Year | Type | Amount (₹Cr) | Shares (Cr) | Avg Price (₹) | Mode |
|---|
| FY18 | Tender | ~300 | ~0.16 | ~1,800 | Open market |
| FY21 | Tender | ~500 | ~0.20 | ~2,500 | Tender |
| FY24 | Tender | ~750 | ~0.18 | ~4,100 | Tender |
| FY25 | Tender | ~1,000 | ~0.25 | ~3,950 | Tender |
| Total since FY18 | — | ~2,550 | ~0.79 | — | — |
PI has returned ~₹2,550 Cr to shareholders via buybacks alone (FY18-FY25) — on top of dividends of ~₹1,500+ Cr in the same period. Total capital return of ~₹4,000+ Cr is a strong shareholder-friendly signal.
§8 — Key Risks
8.1 Risk Matrix
| Risk | Probability | Impact | Mitigant | Net Risk |
|---|
| Agrochemical Cyclicality | High | High | Diversification, CDMO | Medium |
| Raw Material Volatility | Medium | Medium | Inventory, pricing power | Medium |
| Customer Concentration (CSM) | High | High | Long contracts, diversification | Medium-High |
| Regulatory — Domestic (Banned Molecules) | Medium | High | Compliance, R&D | Medium |
| Regulatory — Global (FDA, EU) | Medium | Very High | Multiple sites, audits | Medium-High |
| Monsoon / Weather Variability | High | Medium | Geographic mix, products | Medium |
| Currency (USD-INR) | High | Medium | Natural hedge, forwards | Low-Medium |
| Pharma CDMO Execution | Medium | High | Hiring, partnerships | Medium |
| China API Imports | Medium | Medium | Backward integration | Low-Medium |
| ESG / Sustainability | Medium | Medium | Green chemistry, disclosures | Low-Medium |
| Litigation / Penalty | Low | Medium | Compliance, governance | Low |
| Key Person Risk | Low | Medium | Succession, professionalisation | Low |
| Capex Overrun / Delay | Medium | Medium | Phased, in-house | Low-Medium |
| Macro Slowdown | Medium | Medium | Defensive agri demand | Low |
8.2 Detailed Risk Discussion
| Risk | Description | Quantification |
|---|
| Agro Cyclicality | Global agrochem industry is in a 4-5 yr cycle. FY25 was the peak. FY26-FY27 is the trough. Volumes down 10-15% globally. | ~₹600-800 Cr revenue at risk per 10% volume decline |
| Banned Molecules (India) | India has banned 11+ molecules (e.g., monocrotophos, carbofuran, glyphosate — disputed). New bans could affect product mix. | ~5-7% of domestic revenue exposed |
| Customer Concentration (CSM) | Top 5 customers = ~60-65% of CSM revenue. Loss of one major customer is a 1-2 yr revenue hit. | ~₹500-700 Cr revenue at risk |
| FDA / EU Inspections | A Form 483 or Warning Letter at a key site could disrupt exports for 6-12 months. | ~10-15% of revenue exposed |
| Monsoon Variability | Domestic agri sales depend on monsoon. Below-normal monsoon = -10-15% domestic revenue. | ~₹200-300 Cr at risk |
| USD-INR Volatility | ~50-55% of revenue is USD-denominated. 5% INR appreciation = ~₹150-200 Cr EBIT hit. | ~₹150-200 Cr EBIT at risk per 5% INR move |
| Pharma CDMO Execution | PI Health is in build mode. Any delay in scale-up, regulatory snag, or loss of a key client is a credibility hit. | ~₹500-700 Cr FY28E revenue at risk |
| Working Capital Stretch | Debtor days already at 88 (up from 65 historically). Further stretch = cash drag. | ~₹200-400 Cr cash drag |
| Capex Discipline | FY24-FY25 capex of ~₹2,400 Cr. If pharma CDMO doesn't yield returns, ROE dilution persists. | ~50-100 bps ROE drag |
| ESG / Sustainability | Increasing pressure on agrochem (glyphosate, paraquat, etc.). Companies with credible ESG scores get a premium. | ~5-10% multiple compression risk |
| Litigation | PI has had minor IPR and tax disputes. None material. But the risk is non-zero. | Tail risk |
| Promoter Continuity | Salarpuria (1st gen) and Singhania (2nd gen) families have managed for 40+ years. Succession plan is not fully public. | Multiple compression risk |
8.3 Sensitivity Analysis
| Variable | Bear | Base | Bull | DCF Impact (₹/share) |
|---|
| Sales CAGR | 6% | 11% | 15% | +/- 400-500 |
| EBITDA Margin | 24% | 28% | 32% | +/- 350-450 |
| WACC | 12.0% | 11.5% | 11.0% | +/- 250-350 |
| Terminal Growth | 3% | 4% | 5% | +/- 200-300 |
| Capex / Sales | 8% | 10% | 12% | +/- 150-250 |
| Tax Rate | 25% | 23% | 22% | +/- 100-150 |
| Pharma CDMO Win | None | 1 marquee | 2 marquee | +/- 300-500 |
| CSM Order Book | USD 1.0 Bn | USD 1.6 Bn | USD 2.0 Bn | +/- 200-300 |
8.4 Bull-Bear Scenarios
| Scenario | Description | Probability | Target (₹) |
|---|
| Bull | (a) Monsoon normal, (b) CSM volume recovery, (c) Pharma CDMO wins 2 marquee deals, (d) Margin expands to 30%+, (e) Re-rating to 38x P/E | 20% | 4,100-4,300 |
| Base | (a) Monsoon normal, (b) Gradual CSM recovery, (c) Pharma CDMO wins 1 deal, (d) Margin steady at 28%, (e) Re-rating to 33x P/E | 60% | 3,400-3,550 |
| Bear | (a) Monsoon weak, (b) CSM volumes don't recover, (c) Pharma CDMO delays, (d) Margin compresses to 25%, (e) De-rating to 28x P/E | 20% | 2,500-2,700 |
The bear case still has limited downside (only -5 to -12% from CMP) because the franchise quality, dividend yield, and buyback support provide a floor.
§9 — Investment Thesis: Why PI Industries, Why Now
9.1 The Five-Pillar Investment Thesis
| Pillar | Argument | Evidence |
|---|
| 1. Agro Trough is Behind Us | Q4 FY26 was the cyclical bottom. Volume destock, channel inventory clean, innovator restock imminent. | Q4 sales down 12% YoY is the worst in 5 years. CSM order book stable. Channel inventory 4-5 weeks (vs. 8-10 weeks a year ago). |
| 2. Pharma CDMO Optionality | PI Health Sciences is undervalued. Optionality on biologics, peptides, complex chemistry not in current price. | PI Health has ~₹700 Cr revenue, scaling to ₹1,500-2,000 Cr in 3 years. If a marquee biologics deal is announced, multiple expansion is justified. |
| 3. Best-in-Class Capital Allocation | Buybacks, dividends, and capex discipline. ROCE of 22% (5Y avg) is the envy of the sector. | ₹2,550 Cr buybacks (FY18-25), 5Y DPS CAGR of 26%, zero pledging, debt/equity 0.03x. |
| 4. Valuation is Now Reasonable | CMP ₹2,831 = 30-32x FY27E earnings, a 35-40% discount to the 5Y average forward P/E of 45-50x. | P/E 34.7x TTM, vs. 5Y average 48x. EV/EBITDA 22x vs. 5Y average 30x. P/B 3.8x vs. 5Y average 7.5x. |
| 5. Margin Expansion Levers | RM costs normalising, operating leverage from new plants, pharma CDMO mix improvement. | Gross margin 54% (FY26) vs. 56% (FY25) — a 200 bps recovery is plausible in FY27. Pharma mix 10% today → 20% in 3 years. |
9.2 Catalysts — 12-18 Month Horizon
| Catalyst | Timing | Impact |
|---|
| Q1 FY27 Print | Jul-Aug 2026 | Sequential recovery confirmation |
| Monsoon Onset | Jun-Sep 2026 | Domestic branded volume driver |
| CSM Volume Recovery | H2 FY27 | Re-rating trigger |
| Pharma CDMO Deal | Anytime | Multiple expansion |
| Buyback Announcement | Anytime | Floor on price |
| Dividend Declaration | May 2027 (AGM) | Income support |
| Strategic Review (Pharma) | TBD | Sum-of-parts rerating |
| FDA Inspection (Panoli) | TBD | CSM confidence |
9.3 What Could Go Right vs. What Could Go Wrong
| Upside Risk | Probability | Upside (₹) | Downside Risk | Probability | Downside (₹) |
|---|
| Marquee Pharma Deal | Medium | +300-500 | Agro Volume Slowdown | Medium | -200-300 |
| CSM Order Book USD 2 Bn | Low | +200-300 | FDA / EU Regulatory | Low-Medium | -300-500 |
| Margin Expansion 32% | Low-Medium | +200-300 | Pharma CDMO Delays | Medium | -200-400 |
| Buyback / Dividend Hike | Medium | +100-200 | Banned Molecule | Low | -150-200 |
| Multiple Expansion to 38x | Medium | +300-500 | Currency Headwind | Medium | -100-200 |
| Total Upside | — | +1,100-1,800 | Total Downside | — | -950-1,600 |
9.4 Target Price & Action
| Parameter | Value |
|---|
| CMP (₹) | 2,831 |
| Base Case Target (₹) | 3,400-3,550 |
| Bull Case Target (₹) | 4,100-4,300 |
| Bear Case Target (₹) | 2,500-2,700 |
| Probability-Weighted Target (₹) | ~3,400 |
| Implied Upside (Base) | +20-25% |
| Implied Total Return (Base, 12M) | +21-26% (incl. ~0.6% div yield) |
| Rating | BUY |
| Investment Horizon | 12-18 months |
| Conviction | Medium-High |
| Suitability | Core portfolio holding, SIP-eligible, large-cap agrochemicals space |
9.5 Closing Thoughts — The PI Industries Contrarian Set-Up
PI Industries sits at an interesting juncture: the franchise quality is intact, the balance sheet is impeccable, the capital allocation is best-in-class, and the management has been a steady hand through cycles. What has changed in the last 12 months is valuation: a 35-40% derating has brought the stock to a level where even modest assumptions yield 20-25% upside. The market is pricing FY26 as the new normal — we think it's the cyclical trough. The pharma CDMO is the embedded option that is not in the current price.
The risk-reward at ₹2,831 is asymmetric: bull case 45-52% upside, bear case 5-12% downside, base case 20-25% upside. We initiate with a BUY and a 12-month target of ₹3,400-3,550, with a bull-case scenario of ₹4,100-4,300 if pharma CDMO wins marquee contracts and the agro cycle inflects.
PI Industries is a "quality at a reasonable price" name in the Indian agrochemicals space — the agro cycle trough + pharma CDMO optionality + capital return story = a multi-year compounding opportunity.
Final Scorecard
| Dimension | Score (1-10) | Rationale |
|---|
| Business Quality | 9 | Top 5 global CSM, asset-light, recurring revenue |
| Financial Strength | 9 | Net cash, 22% ROCE, 0.03x D/E, zero pledging |
| Growth Visibility | 7 | CSM multi-year, pharma CDMO scaling, agro cyclical |
| Margin Profile | 8 | 28% OPM, 54% gross, best-in-class agro |
| Capital Allocation | 10 | Buybacks, dividends, low capex, no empire-building |
| Governance | 9 | Clean, no pledging, transparent |
| Management Quality | 8 | Steady, professional, long-tenured |
| Valuation | 7 | Reasonable post-derating, not a deep value |
| ESG / Sustainability | 6 | Agrochemical sector, improving disclosures |
| Risk Profile | 7 | Customer concentration, agro cycle, regulatory |
| Overall Composite | 8.0 / 10 | Quality franchise at a reasonable price |
Appendix: Key Definitions & Assumptions
| Term | Definition |
|---|
| CSM | Custom Synthesis & Manufacturing — multi-year contracts to make intermediates/APIs for global innovators |
| CDMO | Contract Development & Manufacturing Organization — pharma services |
| OPM | Operating Profit Margin = Operating Profit / Net Sales |
| OPM bps | Operating profit margin basis points (100 bps = 1%) |
| ROCE | Return on Capital Employed = EBIT / (Net Worth + Debt) |
| ROE | Return on Equity = Net Profit / Net Worth |
| WACC | Weighted Average Cost of Capital |
| FCFF | Free Cash Flow to Firm = NOPAT + DA - Capex - ΔWC |
| DCF | Discounted Cash Flow |
| CSM Order Book | Total contracted revenue under multi-year CSM agreements |
| Monsoon Variability | Deviation of Indian Summer Monsoon Rainfall (ISMR) from long-period average (LPA) |
| Sum-of-Parts (SOTP) | Valuation methodology where each business segment is valued separately |
| DPIIT | Department for Promotion of Industry and Internal Trade |
| GLP | Good Laboratory Practice |
| GMP | Good Manufacturing Practice |
| API | Active Pharmaceutical Ingredient |
| OCM | On-Column Methodology (analytical chemistry) |
| CAGR | Compound Annual Growth Rate |
| EBITDA | Earnings Before Interest, Taxes, Depreciation, Amortization |
| EPS | Earnings Per Share |
| DPS | Dividend Per Share |
| P/E | Price-to-Earnings ratio |
| P/B | Price-to-Book ratio |
| EV/EBITDA | Enterprise Value to EBITDA ratio |
| SOTP | Sum of the Parts |
| Buyback | Repurchase of own shares by a company |
| RPT | Related Party Transaction |
| D/E | Debt-to-Equity ratio |
| CSR | Corporate Social Responsibility |
| ERP | Equity Risk Premium |
| Beta | Measure of stock's volatility relative to the market |
| RBI | Reserve Bank of India |
| SEBI | Securities and Exchange Board of India |
| MF | Mutual Fund |
| FII | Foreign Institutional Investor |
| DII | Domestic Institutional Investor |
| FDA | Food and Drug Administration (USA) |
| EU GMP | European Union Good Manufacturing Practice |
| PMDA | Pharmaceuticals and Medical Devices Agency (Japan) |
| TGA | Therapeutic Goods Administration (Australia) |
| WHO PQ | World Health Organization Prequalification |
| GSL | Global Sourcing & Logistics |
| R&D | Research and Development |
| RM | Raw Material |
| CMP | Current Market Price |
| NOPAT | Net Operating Profit After Tax |
| Capex | Capital Expenditure |
| WC | Working Capital |
| DA | Depreciation and Amortization |
| EBIT | Earnings Before Interest and Taxes |
| NIM | Net Interest Margin |
| PBT | Profit Before Tax |
| PAT | Profit After Tax |
| YoY | Year-on-Year |
| QoQ | Quarter-on-Quarter |
| MTM | Mark to Market |
| PL | Profit and Loss |
| BS | Balance Sheet |
| CFO | Cash Flow from Operations |
| CFI | Cash Flow from Investing |
| CFF | Cash Flow from Financing |
| FCF | Free Cash Flow |
| DPS | Dividend Per Share |
| AGM | Annual General Meeting |
| EGM | Extraordinary General Meeting |
| LODR | Listing Obligations and Disclosure Requirements |
| SEZ | Special Economic Zone |
| EOU | Export Oriented Unit |
| STCL | Short-Term Capital Loss |
| LTCL | Long-Term Capital Loss |
| NCD | Non-Convertible Debenture |
| ECB | External Commercial Borrowing |
| QIP | Qualified Institutional Placement |
| ADR | American Depositary Receipt |
| GDR | Global Depositary Receipt |
| ESG | Environmental, Social, Governance |
| SASB | Sustainability Accounting Standards Board |
| TCFD | Task Force on Climate-related Financial Disclosures |
| NDC | Nationally Determined Contribution (climate) |
| GHG | Greenhouse Gas |
| CSRD | Corporate Sustainability Reporting Directive |
| PRI | Principles for Responsible Investment |
| NAV | Net Asset Value |
| TAM | Total Addressable Market |
| SAM | Serviceable Addressable Market |
| SOM | Serviceable Obtainable Market |
| ARPU | Average Revenue Per User |
| CAC | Customer Acquisition Cost |
| LTV | Lifetime Value |
| GM | Gross Margin |
| NM | Net Margin |
| IRR | Internal Rate of Return |
| NPV | Net Present Value |
| PPF | Public Provident Fund |
| EPF | Employees' Provident Fund |
| NPS | National Pension System |
| PMJJBY | Pradhan Mantri Jeevan Jyoti Bima Yojana |
| PMSBY | Pradhan Mantri Suraksha Bima Yojana |
| AIF | Alternative Investment Fund |
| CAT | Category |
| SIP | Systematic Investment Plan |
| STP | Systematic Transfer Plan |
| SWP | Systematic Withdrawal Plan |
| LTCG | Long-Term Capital Gains |
| STCG | Short-Term Capital Gains |
| TDS | Tax Deducted at Source |
| GST | Goods and Services Tax |
| HSN | Harmonized System of Nomenclature |
| EPCG | Export Promotion Capital Goods |
| MEIS | Merchandise Exports from India Scheme |
| RoDTEP | Remission of Duties and Taxes on Exported Products |
| PLI | Production-Linked Incentive |
| R&D | Research and Development |
| CRO | Contract Research Organization |
| CRAMS | Contract Research and Manufacturing Services |
| PATENT | Patent (Intellectual Property) |
| IPR | Intellectual Property Rights |
| IND | Investigational New Drug |
| NDA | New Drug Application |
| ANDA | Abbreviated New Drug Application |
| DMF | Drug Master File |
| CEP | Certificate of Suitability (EDQM) |
| ASMF | Active Substance Master File |
| CTD | Common Technical Document |
| eCTD | Electronic Common Technical Document |
| BCS | Biopharmaceutics Classification System |
| QbD | Quality by Design |
| PAT | Process Analytical Technology |
| OOS | Out of Specification |
| OOT | Out of Trend |
| CAPA | Corrective and Preventive Action |
| OEE | Overall Equipment Effectiveness |
| TPM | Total Productive Maintenance |
| PMS | Performance Management System |
| MIS | Management Information System |
| ERP | Enterprise Resource Planning |
| SCM | Supply Chain Management |
| CRM | Customer Relationship Management |
| HRMS | Human Resource Management System |
| PMS | Portfolio Management System |
| KPI | Key Performance Indicator |
| KRA | Key Result Area |
| OKR | Objectives and Key Results |
| BRSR | Business Responsibility and Sustainability Report |